用弗罗塞米德减少化物治疗:急性呼吸系统衰竭儿童的短期影响
Hisataka Nozawa1, Norihiko Tsuboi1, Tadashi Oi1
1Department of Critical Care and Anesthesia, Critical Care Medicine, National Center for Child Health and Development, Tokyo, Japan.
Journal of pediatric intensive care
|November 16, 2023
概括
富洛塞米德扩大了小儿急性呼吸衰竭患者的化差异 (SCD),有助于维持正常的pH水平,尽管持续的高头. 这表明富洛塞米德.
科学领域:
- 儿科重症监护医学 儿科重症监护医学
- 脏生理学 脏生理学
- 酸平衡是指酸平衡的情况.
背景情况:
- 斯图尔特的方法解释说,增加化差异 (SCD) 可以诱导性.
- 富洛塞米德是一种利尿剂,可以改变电解质平衡,包括化物水平.
研究的目的:
- 为了研究furosemide诱导的化物减少对SCD在患有急性呼吸衰竭的儿科患者的影响.
- 为了确定SCD扩张是否会影响该患者群体中的酸平衡 (pH).
主要方法:
- 一项涉及儿科患者的病例控制研究,这些患者因急性呼吸衰竭而被直管.
- 病例组在24小时内接受了罗西米德;对照组在48小时内没有接受罗西米德.
- 测量的主要结果:SCD,PaCO2和pH超过48小时;使用多重回归分析.
主要成果:
- 与对照组相比,罗塞米德组的SCD在48小时后显著增加 (p=0.005).
- 尽管furosemide组的持续性头过高,但pH值在两个组中保持不变,在正常范围内 (p=0.089).
- 无论是SCD还是PaCO2,都与pH (p<0.001) 独立相关.
结论:
- 富洛塞米德诱导的SCD扩张可能有助于在患有急性呼吸衰竭和并发性代谢酸症的儿科患者中维持正常pH值.
- 这种干预可以成为一种有用的策略,用于管理严重疾病儿童的酸干扰.
- 需要进一步的研究来证实这些发现并优化治疗方法.
相关概念视频
Acute Respiratory Failure-V
142
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
142
Acute Kidney Injury V: Interprofessional Care
10
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
10
Heart Failure Drugs: Diuretics
398
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
398
Heart Failure VI: Adjunct Therapies
15
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
15
Renal Failure: Dose Adjustments
95
In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
95
Heart Failure V: Medical Management
9
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
9


